Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in Inpatients

NCT05329363 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-06-17
Last updated
2024-04-23

Condition(s) studied

Schizophrenia

Investigational drug(s) / intervention(s)

PEPITS ProgrammeUsual care

PEPITS Programme: The programme has three main phases: Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and "stepping stone" phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery.

Usual care: Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.

Study summary

Schizophrenia affects about 0.7% of the population. Poor insight, which is common in this disease, linked to poor drug compliance is leads to rehospitalisation with major impact on quality of life. Indeed, many patients relapse with exacerbation of symptoms.

Psychoeducation can improve therapeutic alliance and medication compliance.

In this context, an individual psycho-education program (PEPITS) has been developed. PEPITS carried out by nurses during the initial stages of hospitalisation.

The hypothesis is that PEPITS program will decrease relapse and improve the compliance and insight and and so the quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 65 years * Patient with a diagnosed and reported schizophrenic disorder announced : * Schizophrenia * Schizoaffective disorder * Or a diagnosed and reported Delusional Disorder * Express written consent by the participant after receiving information about the study * Be able to communicate verbally * Participant affiliated to a social security scheme Exclusion Criteria: * Pregnant or breastfeeding woman * Patient who does not speak French * Participation in a psycho-education group in the last 2 years * Patient under legal protection or guardianship

Primary outcome measure(s)

  • Evolution of insight — From inclusion (T0) up to one year (T12) after randomisation
    using the Introspection Self Assessment Questionnaire (IAQ)

Trial sites (11)

FacilityCityRegionStatus
Serrvice de Psychiatrie Blois France Withdrawn
Service de psychiatrie Chinon France Recruiting
Service de psychiatrie Dreux France Not Yet Recruiting
Service de psychiatrie Fleury-les-Aubrais France Withdrawn
Service de psychiatrie La Roche-sur-Yon France Recruiting
Service de psychiatrie Neuilly-sur-Marne France Not Yet Recruiting
Service de psychiatrie Rennes France Recruiting
Service de psychiatrie Saint-Maurice France Not Yet Recruiting
Service de psychiatrie Sainte-Gemmes-sur-Loire France Recruiting
Service de psychiatrie Sotteville-lès-Rouen France Not Yet Recruiting
Service de psychiatrie Tours France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05329363 on ClinicalTrials.gov ↗ ← All trials in France